-
Hotel Blacklist Launches New Accommodation Industry Risk Assessment Tool
-
Messi says Argentina retirement is 'saddest day of my career'
-
Bangladesh nuclear plant draws hope -- and worry
-
Oil rises and stocks fall as Hormuz worries flare
-
US beat Canada 1-0 to wrap up four-win international break
-
Pacific presses world for help 'surviving' climate change at pre-COP summit
-
Turkey, Australia's joint COP31 leadership raises doubts
-
Verstappen revival to be put to the test in steamy Singapore
-
For Turkish NGOs, COP31 offers rare space for action
-
US woman who survived botched execution is conscious, speaking: lawyers
-
Sleep, appetite, gene-editing experts contend for Nobel chemistry prize
-
Climate champion Australia digging more coal
-
Nobel Peace Prize haunted by the 'spectre' of Trump
-
Emotion, tears as Messi retires from Argentina national team
-
Africa launches own credit agency in bid for cheaper borrowing
-
Dodgers push Braves to the brink of MLB playoff exit
-
US, China, EU: three paths to regulating AI
-
Crisis-stricken Haiti postpones elections
-
Australia's High Court rules against coal mine in landmark climate case
-
N. Korea's Kim pledges 'invariable support' in Putin birthday letter
-
Australia touts new funds for Pacific infrastructure at Fiji 'pre-COP'
-
OGRD Alliance Advances PLPC Multi-Asset Platform Following APHELAR Milestone, Expanding Licensing and Strategic Capital Frameworks
-
Eva Marie Saint, Oscar winner of Hollywood classics, dies at 102
-
Emotion, tears as Messi prepares for Argentina farewell
-
Australia probes app used in cheap smart glasses over privacy fears
-
Kane eyes Ronaldo record after matching England cap mark
-
England needed to 'move on' from World Cup pain, says Tuchel
-
Spain fight back to beat Croatia, Kane adds to record for England
-
O'Neill to stay at Celtic after period of "reflection"
-
Merino double helps Spain beat Croatia, reach Nations League quarters
-
Kane marks 125th England cap with Wembley Nations League double
-
US stocks hit fresh records as oil stabilizes on rising supplies
-
Quebec's incoming separatist leader wants to block Crown from swearing-in
-
As Messi bows out, Argentines say 'thank you'
-
Emmys gala will now stream its premier television awards
-
Ronaldo opens door for Portugal return, apologises for walkout
-
Paramount completes Warner Bros takeover, creating Skydance
-
'Nobody seems to care': Russian city shrugs off plague reports
-
Trump blames France unrest on Islam, migration
-
Hundreds arrested in French school protests as Macron summons ministers
-
Apple's Cook praises EU over efforts to protect children online
-
WADA seeks tough anti-doping stance from Kenya
-
Nobel winner Halzen says years of October 'misery' finally over
-
German ex-spy chief arrested for suspected espionage, treason
-
Quebec separatist win rattles Carney's unity push
-
Furyk vows US will 'do more' to end Ryder Cup losing streak
-
'Itching' for change: Shiffrin cuts back slaloms this season
-
Iyer hits ton as India hammer West Indies in T20 opener
-
'Gen Z has risen up': Tens of thousands mass for tense France school protests
-
Mandhana named India women's team captain after Kaur quits
Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
V.Said--SF-PST